Patents by Inventor Christophe PIKETTY

Christophe PIKETTY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENTS FOR PRURIGO NODULARIS
    Publication number: 20240141050
    Abstract: Described herein are treatments and preventions for prurigo nodularis (PN), antibodies and pharmaceutical compositions for use in the treatment or prevention of PN, and uses of an anti-IL-31RA antibody (e.g., nemolizumab) in the manufacture of a medicament for the treatment or prevention of PN. Also described herein are biomarkers of PN and methods of altering or improving these biomarkers via treatments with an antibody that binds to IL-31RA (e.g., nemolizumab).
    Type: Application
    Filed: August 25, 2023
    Publication date: May 2, 2024
    Inventors: Valerie JULIA, Jayendra Kumar KRISHNASWAMY, Christophe PIKETTY, Francois ROUSSEAU
  • TREATMENTS FOR ATOPIC DERMATITIS
    Publication number: 20230242652
    Abstract: Described herein are treatments and preventions for atopic dermatitis (AD), antibodies and pharmaceutical compositions for use in the treatment or prevention of AD, and uses of an anti-IL-31RA antibody (e.g., nemolizumab) in the manufacture of a medicament for the treatment or prevention of AD. Also described herein are biomarkers of AD and methods of altering or improving these biomarkers via treatments with an antibody that binds to IL-31RA (e.g., nemolizumab).
    Type: Application
    Filed: August 29, 2022
    Publication date: August 3, 2023
    Applicant: Galderma Holding S.A.
    Inventors: Jayendra Kumar KRISHNASWAMY, Christophe PIKETTY
  • TREATMENTS FOR PRURIGO NODULARIS
    Publication number: 20220411518
    Abstract: Described herein are treatments and preventions for prurigo nodularis (PN), antibodies and pharmaceutical compositions for use in the treatment or prevention of PN, and uses of an anti-IL-31RA antibody (e.g., nemolizumab) in the manufacture of a medicament for the treatment or prevention of PN. Also described herein are biomarkers of PN and methods of altering or improving these biomarkers via treatments with an antibody that binds to IL-31RA (e.g., nemolizumab).
    Type: Application
    Filed: April 6, 2022
    Publication date: December 29, 2022
    Inventors: Valerie JULIA, Jayendra Kumar KRISHNASWAMY, Christophe PIKETTY, Francois ROUSSEAU
  • TREATMENT OF SKIN LESIONS AND PRURITUS IN PRURIGO NODULARIS PATIENTS
    Publication number: 20220177568
    Abstract: Disclosed herein are methods for selectively treating pruritus in a subject having chronic prurigo (CP), including prurigo nodularis (PN), pharmaceutical compositions for use in the treatment of pruritus in a subject having CP or PN, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of pruritus in a subject having CP or PN.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 9, 2022
    Applicant: Galderma Holding SA
    Inventor: Christophe PIKETTY
  • Treatment of skin lesions and pruritus in prurigo nodularis patients
    Patent number: 11236157
    Abstract: Disclosed herein are methods for selectively treating pruritus in a subject having chronic prurigo (CP), including prurigo nodularis (PN), pharmaceutical compositions for use in the treatment of pruritus in a subject having CP or PN, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of pruritus in a subject having CP or PN.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: February 1, 2022
    Assignee: Galderma Holding SA
    Inventor: Christophe Piketty
  • TREATMENT OF SKIN LESIONS AND PRURITUS IN PRURIGO NODULARIS PATIENTS
    Publication number: 20200239563
    Abstract: Disclosed herein are methods for selectively treating pruritus in a subject having chronic prurigo (CP), including prurigo nodularis (PN), pharmaceutical compositions for use in the treatment of pruritus in a subject having CP or PN, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of pruritus in a subject having CP or PN.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 30, 2020
    Applicant: NESTLÉ SKIN HEALTH S.A.
    Inventor: Christophe PIKETTY